Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Threonine 99% | Threonine 99%, CAS 72-19-5, Amino Acids. Formerly Lansdowne Chemicals | OQEMA England, Oxfordshire |
| 2,3,4,6-Tetra-O-acetyl-b-D-galactopyranosyl-(N2-Fmoc)-L-threonine | 2,3,4,6-Tetra-O-acetyl-b-D-galactopyranosyl-(N2-Fmoc)-L-threonine is a biomedical compound commonly utilized in the development and synthesis of peptide-based drugs. It plays a crucial role as a protecting group for the amino acid threonine during peptide synthesis. With its precise chemical properties, it ensures the accurate and controlled assembly of peptide sequences, making it an tool in drug development and disease research. Group: Pharmaceutical. CAS No. 127656-85-3. Pack Sizes: 100 mg. Product ID: BAT-008970. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-b-D-glucopyranosyl-Fmoc threonine | 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-b-D-glucopyranosyl-Fmoc threonine is a glycosylated amino acid used in the synthesis of Fmoc solid-phase peptide. Group: Pharmaceutical. CAS No. 160168-40-1. Pack Sizes: 100 mg. Product ID: BAT-015387. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acetyl-L-threonine | Acetyl-L-threonine. Group: Pharmaceutical. CAS No. 17093-74-2. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-003877. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acetyl-L-threonine methyl ester | Acetyl-L-threonine methyl ester. Group: Pharmaceutical. CAS No. 2458-78-8. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-003878. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acetyl-O-tert-butyl-L-threonine | Acetyl-O-tert-butyl-L-threonine. Group: Pharmaceutical. CAS No. 163277-80-3. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-003885. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| DL-Threonine | 100g Pack Size. Group: Amino Acids, Biochemicals. Formula: C4H9NO3. CAS No. 80-68-2. Prepack ID : 19522182-100g. Molecular Weight : 119.12. |  |
| DL-Threonine | 25g Pack Size. Group: Amino Acids, Biochemicals. Formula: C4H9NO3. CAS No. 80-68-2. Prepack ID : 19522182-25g. Molecular Weight : 119.12. | |
| Fmoc-L-Threonine | 25g Pack Size. Group: Amino Acids. Formula: C19H19NO5. CAS No. 73731-37-0. Prepack ID : 61802005-25g. Molecular Weight : 341.36. | |
| H-D-allo-Threonine Methyl Ester Hydrochloride | H-D-allo-Threonine Methyl Ester Hydrochloride is used to prepare hepatitis A virus 3C cysteine protease inhibitors. Group: Pharmaceutical. CAS No. 60538-18-3. Pack Sizes: 1 g. Product ID: B2699-039416. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| L-Threonine | 100g Pack Size. Group: Amino Acids. Formula: C4H9NO3. CAS No. 72-19-5. Prepack ID : 29578582-100g. Molecular Weight : 119.12. | |
| L-Threonine | 500g Pack Size. Group: Amino Acids. Formula: C4H9NO3. CAS No. 72-19-5. Prepack ID : 29578582-500g. Molecular Weight : 119.12. | |
| L-Threonine | L-Threonine Uses: Pharmaceutical Research and Development. Group: Intermediates. CAS No. 72-19-5. Pack Sizes: Enquire for MOQ. Categories: NORDMANN innovative sourcing and supply. |  UK / EU / USA / Japan |
| Alisertib | MLN8237 is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Group: Pharmaceutical. CAS No. 1028486-01-2. Pack Sizes: 100 mg. Product ID: B2693-336876. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AR-A014418 | AR-A014418 is an ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK-3β), a serine/threonine protein kinase involved in multiple diseases including Alzheimer's disease and type 2 diabetes. Group: Pharmaceutical. CAS No. 487021-52-3. Pack Sizes: 25 mg. Product ID: B0084-258809. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AT9283 | AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50= 3, 3, 1.2, 1.1, and 4 nM, respectively). It also potently (IC50 = <1 μM) inhibits serine/threonine kinases as well as receptor and non-receptor tyrosine kinases. Group: Pharmaceutical. CAS No. 896466-04-9. Pack Sizes: 10 mg. Product ID: B0084-100114. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AZD-5363 | AZD-5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD-5363 binds to and inhibits all AKT isoforms. This agent may be used as monotherapy or combination therapy for a variety of human cancers. Group: Pharmaceutical. CAS No. 1143532-39-1. Pack Sizes: 10 mg. Product ID: B2693-457058. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| BX-795 | 3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a serine-threonine kinase that phosphorylates and activates a range of other kinases, including PKB, PKA, and certain isoforms of PKC. BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, which is 140- and 1600-fold more selective than PKA and PKC. It is also a potent and relatively specific inhibitor of TBK1 with IC50 of 6 nM and IKK? with IC50 of 41 nM. Group: Pharmaceutical. CAS No. 702675-74-9. Pack Sizes: 25 mg. Product ID: B0084-194478. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| C16 Ceramide | C16 ceramide is an endogenous ceramide, generated by ceramide synthase 6 (CerS6), that acts as a lipid second messenger to regulate apoptosis and stress signaling. It has also been found to activate NF-κB and PKCζ3. Uses: A predominant, rather hydrophobic natural ceramide. activates a cytosolic serine/threonine protein phosphatase in t9 cells; induces egf receptor phosphorylation in a-431 cells; stimulates ceramide-activated protein kinase. Group: Pharmaceutical. CAS No. 24696-26-2. Pack Sizes: 100 mg. Product ID: B1370-059982. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Cobimetinib | Cobimetinib (GDC-0973, RG7420) is a potent, orally available and highly selective MEK1 inhibitor with IC50 of 4.2 nM. It shows more than 100-fold selectively for MEK1 over MEK2 when tested against a panel of more than 100 serine-threonine and tyrosine kinases and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Group: Pharmaceutical. CAS No. 934660-93-2. Pack Sizes: 25 mg. Product ID: B0084-460683. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Group: Pharmaceutical. CAS No. 1269440-17-6. Pack Sizes: 150 mg. Product ID: B0084-462563. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Group: Pharmaceutical. CAS No. 929095-18-1. Pack Sizes: 10 mg. Product ID: B0084-307746. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GSK583 | GSK583 is a selective receptor-interacting serine/threonine-protein kinase 2 (RIP2 Kinase) inhibitor and the RIP2K binding IC50 is 5 nM. GSK583 can inhibit both TNF-α and IL-6 production with an IC50 value of 200 nM in an ex vivo human translational model. Group: Pharmaceutical. CAS No. 1346547-00-9. Pack Sizes: 25 mg. Product ID: B0084-475334. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| HMN-214 | HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kinase that regulates critical mitotic events. Group: Pharmaceutical. CAS No. 173529-46-9. Pack Sizes: 50 mg. Product ID: B2693-321779. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ipatasertib | Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GDC-0068 binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Uses: Antineoplastic agents. Group: Pharmaceutical. CAS No. 1001264-89-6. Pack Sizes: 50 mg. Product ID: B2693-456282. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Linifanib | Description of Linifanib: Linifanib is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3). Group: Pharmaceutical. CAS No. 796967-16-3. Pack Sizes: 200 mg. Product ID: B0084-151820. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Marizomib | Marizomib is a naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues. Group: Pharmaceutical. CAS No. 437742-34-2. Pack Sizes: 1 mg. Product ID: BBF-05732. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Milciclib | Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types. Group: Pharmaceutical. CAS No. 802539-81-7. Pack Sizes: 5 mg. Product ID: B0084-459709. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| NMS-1286937 | NMS1286937, also know as NMS-P937, is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor NMS-1286937 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressing tumor cells. PLK1 is a serine/threonine protein kinase crucial in the regulation of mitosis. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 1034616-18-6. Pack Sizes: 500 mg. Product ID: B1370-462742. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| PD0325901 | PD-0325901 is a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. Uses: Reprogramming, self-renewal. Group: Pharmaceutical. CAS No. 391210-10-9. Pack Sizes: 100 mg. Product ID: B0084-091588. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| PF-04691502 | PF-04691502 is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. It inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. Group: Pharmaceutical. CAS No. 1013101-36-4. Pack Sizes: 50 mg. Product ID: B0084-456382. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| PF-06650833 | PF-06650833 is an inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), which is an omnipresently expressed serine/threonine kinase involved in the regulation of innate immunity. PF-06650833 is useful for the treatment of autoimmune and inflammatory diseases associated with lnterleukin-1 Receptor Associated Kinase (IRAK) and more particularly modulates the function of IRAK. It is undergoing testing in a Phase II clinical study. Group: Pharmaceutical. CAS No. 1817626-54-2. Pack Sizes: 25 mg. Product ID: B0084-474124. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Regorafenib | Regorafenib, also known as BAY 73-4506, is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. Regorafenib is demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the US FDA on September 27, 2012. Uses: Antineoplastic agent. Group: Pharmaceutical. CAS No. 755037-03-7. Pack Sizes: 500 mg. Product ID: BBF-05856. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| RGB-286638 Free base | RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated equimolar (50nM) activity in freshly isolated tumor cells from MM patients, while manifesting less cytotoxicity in healthy donor PBMCs. It reduced the phosphorylation of Rb at S807/811 in MM.1S and MM.1R cells, but had no effects on p-Rb S780. Group: Pharmaceutical. CAS No. 784210-88-4. Pack Sizes: 100 mg. Product ID: B0084-463330. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Rigosertib sodium | Rigosertib (ON-01910 sodium salt), a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Group: Pharmaceutical. CAS No. 1225497-78-8. Pack Sizes: 50 mg. Product ID: B0084-286621. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Seliciclib | Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2/E, CDK2/A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Mcl-1 belongs to the Bcl-2 family of antiapoptotic proteins and is a protein crucial to the survival of a range of tumor cell types. Group: Pharmaceutical. CAS No. 186692-46-6. Pack Sizes: 100 mg. Product ID: B1370-086385. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Tozasertib | The Aurora kinases (A, B, and C) are a family of serine-threonine kinases that regulate various stages of mitotic function. With significant roles in cell cycle and cell division, Aurora kinase gene amplification and overexpression are linked to tumorigenesis. MK 0457 is a potent pan-Aurora kinase inhibitor but favors Aurora A (Ki = 0.6 nM) over Aurora B (Ki = 18 nM) or Aurora C (Ki = 4.6 nM). It shows selectivity against a panel of more than 190 different protein kinases. MK 0457 effectively inhibits proliferation of several different cell lines of clear cell renal carcinoma (IC50s < 10 μM) and blocks the growth of tumors in a rodent model of cancer (80 mg/kg), inhibiting histone H3 phosphorylation and increasing apoptosis. By depleting Aurora activity, MK 0457 disrupts bipolar spindle formation during mitosis, arresting cell cycle progression at the G2/M phase. Group: Pharmaceutical. CAS No. 639089-54-6. Pack Sizes: 250 mg. Product ID: B0084-074159. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Tricirbine | Triciribine is a potent AKT inhibitor and a cell-permeable tricyclic nucleoside molecule with potential antineoplastic activity. Akt-1, -2, and -3 are serine/threonine protein kinases in the phosphatidylinositol (PI3)-kinase signalling pathway that play a critical role in the regulation of cell proliferation and survival. Following recruitment of Akt to the plasma membrane, phosphorylation at threonine 308 and serine 473 (Akt-1 numbering) by phosphoinositide-dependent kinases (PDK) 1 and 2 results in full activation of the enzyme. Triciribine is a cell-permeable tricyclic nucleoside that inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3. It does not inhibit phosphatidylinositol 3 (PI3)-Kinase or PDK1, the direct upstream activators of Akt, nor does it inhibit PKC, PKA, ERK1/2, serum- and glucocorticoid-inducible kinase, p38, STAT3, or JNK signalling pathways. Triciribine effectively inhibits growth of Akt-overexpressing human cancer cell lines in vitro with 50% inhibition at ~5-10 μM. It also inhibit growth of tumor xenografts in mice by greater than 80% at a dose of 1 mg/kg/day. Group: Pharmaceutical. CAS No. 35943-35-2. Pack Sizes: 100 mg. Product ID: B1370-090988. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Uprosertib | Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Group: Pharmaceutical. CAS No. 1047634-65-0. Pack Sizes: 25 mg. Product ID: B0084-462537. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| YKL-06-061 | YKL-06-061 is a small molecule serine/threonine-protein kinase SIK1 inhibitor (Ki = 6.56 nM) that is hopefully developed to be a dermatologic drug impacting UV protection and skin cancer risk. It causes a dose-dependent increase in microphthalmia-associated transcription factor (MITF) mRNA expression during 3-hour function in normal human melanocytes, UACC62 human melanoma cells, and UACC257 human melanoma cells. Uses: A potential dermatologic drug. Group: Pharmaceutical. CAS No. 2172617-15-9. Pack Sizes: 50 mg. Product ID: B0084-112344. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
